Sjöberg J. 15-Lipoxygenase-1 induces expression and release of chemokines in cultured human lung epithelial cells.
airway epithelial cells; asthma; arachidonic acid ASTHMA is a chronic airway inflammatory disease characterized by infiltration of mast cells, activated T cells, and eosinophils in the respiratory tract. Chemokines are crucial recruiters and activators of these inflammatory cells and play an important role in the pathogenesis of inflammatory lung diseases (15) . The enzyme 5-lipoxygenase (5-LOX) catalyzes the first step in the conversion of arachidonic acid to leukotrienes, which are potent bronchoconstrictors and proinflammatory mediators (9) . 15-LOX-1 is another related lipoxygenase that catalyzes the insertion of molecular oxygen at the 6 position in various polyunsaturated fatty acids.
Mediators formed via the 15-LOX-1 pathway include 15(S)-hydroxyeicosatetraenoic acid [15(S)-HETE] from arachidonic acid and 13(S)-hydroxyoctadecadienoic acid [13(S)-HODE] from linoleic acid.
15-LOX-1 has been proposed to be involved in various physiological and pathophysiological activities including cell differentiation and maturation, tumorigenesis, apoptosis, and inflammation-related diseases including asthma, chronic obstructive pulmonary disease, diabetic vascular disease, and atherosclerosis (5, 8, 22, 26, 33) . The enzyme is predominantly expressed in reticulocytes, eosinophils, macrophages, mast cells, and bronchial epithelial cells (5, 14) . In human airways, 15-LOX-1 is mainly found in the bronchial epithelium, infiltrating eosinophils, and mast cells (3, 8, 14, 17, 19, 34) .
The inflammatory response in asthma is characterized by a type II immune reaction with high tissue levels of T helper cell type 2 (Th2) cytokines, including IL-4 and IL-13, which are known inducers of 15-LOX-1 expression in various kinds of cells (4, 11, 14, 24) . Elevated concentrations of 15(S)-HETE have been demonstrated in bronchoalveolar lavage fluid after allergen challenge in mild atopic asthmatics, accompanied by increased 15-LOX-1 expression in bronchial epithelium (7) . Similarly, increased 15(S)-HETE levels were reported in chronic asthma, and an increased proportion of 15-LOX-1 mRNA-positive macrophages was found in induced sputum (28) . Furthermore, it has been shown that the expression of 15-LOX-1 in bronchial epithelial cells is significantly higher in patients with asthma and chronic bronchitis than in healthy subjects (33) , although the role of 15-LOX-1 metabolites in these disorders is not clear. Very recently, though, we reported on eoxins, which are proinflammatory mediators formed via the 15-LOX-1 pathway in human eosinophils and mast cells (8, 13) . In addition, in human polymorphonuclear leukocytes, 13(S)-HODE induces chemotaxis at submicromolar concentrations (16) . Knocking down 12/15-LOX, the ortholog of human 15-LOX-1, in mouse vascular smooth muscle cells by short interfering RNAs leads to downregulation of the expression of inflammatory genes including IL-6 (18, 21) . Mice deficient of 12/15-lipoxygenase also had an attenuated allergic airway inflammation compared with wild-type mice (1) . In contrast, the results of other studies suggest that 15-LOX-1 is an anti-inflammatory enzyme. For instance, 15(S)-HETE inhibits the activity of 5-LOX in neutrophils, leading to reduced production of leukotrienes (5) , and transfection of rat kidney cells with human 15-LOX-1 suppresses inflammation in experimental glomerulonephritis (23) . Furthermore, lipoxins, which could partially be formed via the 15-LOX-1 pathway, also have anti-inflammatory properties (5) .
Given the complex role of 15-LOX-1 and the emerging view of the importance of the epithelial cells in the orchestration of the asthmatic inflammatory response (6), we transiently expressed 15-LOX-1 in cultured human airway epithelial cells, as a model to study the overall function of this enzyme in human bronchial cells and airway inflammation.
MATERIALS AND METHODS

Cell Culture
Human A549 airway epithelial cells were maintained at 37°C in RPMI 1640 medium supplemented with 10% FCS, 2 mM glutamine, and antibiotics (100 U/ml penicillin and streptomycin). Peripheral blood mononuclear cells (PBMC) from healthy donors were isolated by density gradient centrifugation with Ficoll (Amersham, Uppsala, Sweden). Monocyte-derived immature dendritic cells (iDC) were generated as described previously (30, 38) . Briefly, isolated PBMC (5-10 ϫ 10 6 /ml) were plated in complete RPMI containing 10% FCS and allowed to adhere for 2 h at 37°C. Nonadherent cells were removed, and the adherent cells were washed three times with PBS. Complete RPMI containing 10% FCS, 1,000 U/ml IL-4, and 100 ng/ml GM-CSF was added, and the cells were cultured for 6 -7 days. Cord blood-derived mast cells were provided by Dr. Gunnar Nilsson (Karolinska Institutet, Stockholm, Sweden) (12) . T cells from healthy donors were isolated with MACS Pan T Cell Isolation Kit based on negative selection with a cocktail of hapten-conjugated antibodies (Miltenyi Biotec) and were stimulated with 5 g/ml phytohaemagglutanin (PHA) for 4 days followed by 150 U/ml IL-2 for 11 days in complete RPMI containing 10% FCS. The study was approved by the local ethics committee. The MucilAir primary cells, used in one experiment in this study (Fig. 1B) , originated from human airway epithelium from healthy subjects (purchased from Epithelix Sàrl, Switzerland). The cells were terminally differentiated, cultivated as a monolayer on Transwell clear inserts (Costar) with ϳ400 000 cells/ well. The cells were cultivated in the absence or presence of IL-4 (20 ng/ml) for 5 days. 15(S)-HPETE, 15(S)-HETE, 13(S)-HPODE, or 13(S)-HODE (Biomol) stocks were dissolved in DMSO.
Vectors
A 1.7-kb 15-LOX-1 cDNA fragment without 3Ј-UTR derived from human dendritic cells was inserted into pLP-IRESneo by Creator recombinant kit (Clontech). Expression of the bicistronic message is driven by the human cytomegalovirus (CMV) major immediate early promoter. The sequence of the insert in the pLP-IRESneo vector was confirmed by sequencing in two directions. The pNF-B-Luc plasmid was purchased from Stratagene (La Jolla, CA).
Preparation of RNA Samples and Gene Chip Hybridization
Total RNA from transfected A549 cells was purified (according to the manufacturer's protocol) with RNeasy purification kit (Qiagen, Germany) and then used to generate cRNA probes. Preparation of cRNA, hybridization, and scanning of the human genome U133 plus 2.0 arrays (Affymetrix, Santa Clara, CA) were performed according to the manufacturer's protocol. Probe intensities were extracted from the image by GeneArray scanner and Microarray Suite 4.0.
Quantitative Real-Time RT-PCR
cDNA synthesis, reverse transcription-PCR primers, and conditions for 15-LOX-1 cDNA preparation were described previously (20) . RT-real-time PCR with 3 l of cDNA was performed in an ABI 7700 sequence detector (Applied Biosystems, Foster City, CA) using Pre-made Gene Expression Assays (Applied Biosystems) primers and probes for 15-LOX-1 (Hs00609608_m1), MIP-1␣ (Hs00234142_m1), RANTES (Hs00174575_m1), and IP-10 (Hs00171042_m1). Levels of transcripts were expressed as the ratio vs. human ␤ 2 microglobulin (Hs00187842_m1).
siRNA Treatment
Chemically modified Stealth siRNA targeting 15-LOX-1 (sequence: UAAAGAGACAGGAAACCCUCGGUCC) and control siRNA were purchased from Invitrogen. siRNA transfection was done using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol.
Analysis of Chemokine Concentrations in Conditioned Medium
The concentration of chemokines in conditioned medium of A549 cells was measured by Multiplex Luminex Assay (Biosource, Invitrogen) and ELISA kit (R&D Systems) according to the manufacturer's protocols.
Western Blotting
For detection of 15-LOX-1 protein, whole cell extracts were separated on a 4 -20% polyacrylamide gel (Bio-Rad) and transferred onto nitrocellulose membranes. After being blocked with 5% nonfat dry milk in PBS containing 0.1% Tween 20, the nitrocellulose membranes were incubated with 15-LOX-1 antiserum (1:1,000 dilution) for 1 h at room temperature. This polyclonal 15-LOX-1 antiserum was raised in rabbit against recombinant human 15-LOX-1 (the enzyme was expressed in Sf9 cells and purified by ion exchange chromatography before immunization; the purity of the enzyme preparation was Ͼ95%). The antiserum was developed by Innovagen (Ideon, Lund, Sweden) and did not detect human 5-LOX, platelet 12-LOX, or 15-LOX-2 (data not shown) (14) . Following incubation with goat anti-rabbit (1:5,000 dilution) IgG-horseradish peroxidase as second antibody, proteins were visualized using ECL solutions (Amersham) as described by the manufacturer.
Incubation of A549 with Arachidonic Acid
The cell suspension (3 ϫ 10 6 cells/incubation) was preincubated with indomethacin (1 M) (Sigma-Aldrich, St. Louis, MO) at 37°C for 2 min to inhibit cyclooxygenase activity. Cells were further incubated at 37°C for 5 min with arachidonic acid (40 M) (Nu-Chek Prep, Elysian). Incubations were terminated by the addition of 1 vol of methanol, and samples were placed on ice. Cell supernatants were analyzed with reverse phase (RP) HPLC.
Analysis of Arachidonic Acid Metabolites
Metabolite extraction. Samples were centrifuged (1,400 g, 6 min), and the supernatants diluted with water were transferred to a washed and equilibrated extraction cartridge, Oasis HLB 1 ml/10 mg (Waters, Sweden). The samples were applied to the extraction column, and after being washed with water, the metabolites were eluted with methanol.
HPLC analysis. One volume of water was added to the sample before injection. RP-HPLC was performed using a Nova-Pak C18 column (2.1 ϫ 150 mm, Waters) with a stepwise solvent gradient and flow rate maintained at 0.4 ml/min. Mobile phase A consisted of 0.05% acetic acid, pH adjusted to 5.6, with 25% ammonium acetate, and mobile phase B consisted of acetonitrile:methanol 60:40. All solvents used were of HPLC grade and bought from Skandinaviska GeneTech (Stockholm, Sweden). A 5-min isocratic gradient of 100% mobile phase A was followed by a 15-min linear gradient reaching 36% of mobile phase B. This was continued by 100 min of isocratic elution with mobile phase ratio of A:B 64:36. Next, a 20-min linear gradient was applied to reach 70% B. UV spectra were acquired between 210 and 330 nm using diode array detection (PDA 996, Waters). Retention times and UV absorbance spectra of peaks in the chromatogram were compared with synthetic standards of 15 
15(S)-HETE Assay
The capacity to produce 15(S)-HETE was used as a marker of 15-LOX-1 activity in the cells. The levels of 15(S)-HETE were quantified by EIA Kit (Cayman) according to the manufacturer's protocol if not otherwise indicated.
Chemotaxis Assay
Chemotaxis assays were performed using transwell cell culture chambers (24 wells) with gelatin-coated polycarbonate filters (pore size, 8 m; Costar). Cells (10 5 in 100 l 1% FCS RPMI) were added to the upper wells, and 600 l A549 culture medium was added to the lower wells. After 2 h of incubation at 37°C, the filters were washed three times in PBS, fixed in methanol/acetone (1:1) for 5-10 min at Ϫ20°C, and stained with Mayer's hematoxylin and eosin (Histolab Products). Cells remaining on the upper side of the filters were scraped off with a cotton swab. Cells on the lower side of the filters were counted by light microscopy at ϫ40 magnification in 12 randomly selected fields per well. For antibody neutralization experiments, mouse monoclonal antibodies against MIP-1␣ (MAB670, R&D Systems), MIP-1␤ (MAB271), RANTES (MAB678), IP-10 (MAB266), or I-TAC (MAB672) or isotype control antibodies (mouse IgG1 for anti-RANTES and anti-IP-10 antibodies, IgG2a for anti-MIP-1␣ and anti-I-TAC antibodies, IgG2b for anti-MIP-1␤ antibody) were added to the transwell with the final concentration of 5 g/ml. All antibodies used were purchased from R&D Systems except mouse IgG2a isotype control antibody (Dako). In the double antibody depletion experiments, 5 g/ml mouse IgG1 and 5 g/ml IgG2a isotype control antibodies were used.
Statistics
Data are presented as means Ϯ SE. Wilcoxon signed rank test was used for comparison of paired observations, except for the chemotaxis assay data, for which Student's t-test was used.
RESULTS
15-LOX-1 Expression and Enzymatic Activity in A549 Cells Transiently Transfected with 15-LOX-1/pLP-IRESneo
To evaluate the biological function of 15-LOX-1 in airway epithelial cells, we transiently transfected A549 cells with a vector expressing 15-LOX-1 cDNA cloned from normal human dendritic cells (pLP-IRESneo/15-LOX-1) or empty vector (pLP-IRESneo) as negative control. The A549 cell line was used as a model in this study because it originates from airway epithelial cells and has inducible 15-LOX-1 expression (4, 32). The 15-LOX-1 transcription can be induced by IL-4 in these cells, but the activity of the enzyme is still relatively low (32) . Therefore, the enzyme was ectopically overexpressed in A549 cells by transient transfection. The expression of the enzyme was confirmed by real-time PCR at the mRNA level and Western blot at the protein level (Fig. 1, A and B) . To investigate whether the degree of overexpression of 15-LOX-1 that is induced in the A549 cells after transfection is comparable to what is seen in normal human cells, the 15-LOX-1 expression in normal airway epithelial cells ex vivo, with or without IL-4 stimulation, was evaluated in parallel by Western blot analysis. The transfected A549 cells expressed comparable amounts of 15-LOX-1 protein as normal human airway epithelial cells (Fig. 1B) . Furthermore, normal human airway epithelial cells treated with IL-4 expressed even higher levels of 15-LOX-1 than transfected A549 cells (Fig. 1B) .
Both qualitative and quantitative methods were employed to measure the catalytic activity of 15-LOX-1 ectopically expressed in A549 cells. Twenty-four hours posttransfection, different 15-LOX-1-derived metabolites from exogenous arachidonic acid were identified by HPLC. As shown in Fig. 1C , cells expressing 15-LOX-1 produced 15-HETE, whereas this metabolite was barely detected in cells transfected with the empty vector. Furthermore, 8,15-DiHETEs (four isomers) and 15-KETE were only produced by the 15-LOX expressing cells and not in cells transfected with empty vector only. We also used ELISA to quantify the levels of 15-HETE after 15-LOX-1 transfection (Fig. 1D) . A time course study showed that the A549 cells had the highest 15-LOX-1 enzymatic activity 24 h posttransfection. Thereafter, the activity of 15-LOX-1 began to gradually decrease, probably because of either the dilution effect of cell proliferation or the metabolism of 15-LOX-1 protein/metabolites. Cells transfected with empty vector as a control had low capacity to produce 15-HETE, indicating a very low endogenous 15-LOX-1 activity (Fig. 1D) .
15-LOX-1 Induces Chemokine Expression in A549 Cells
Based on microarray analysis at 24 h posttransfection in three independent experiments, we found that gene expression of the chemokines MIP-1␣ (CCL3), MIP-1␤ (CCL4), RANTES (CCL5), MIP-3a (CCL20), GRO3 (CXCL3), IP-10 (CXCL10), I-TAC (CXCL11), and fractalkine (CX3CL1) was upregulated Ͼ3 times (mean) by transfection with 15-LOX-1/ pLP-IRESneo compared with empty vector. Out of these, MIP-1␣, RANTES, and IP-10 were selected for further analysis, and their induction was confirmed by RT-PCR (data not shown) and real-time PCR (Fig. 2A) . To exclude the possibility that the induction of chemokine expression was due to a nonspecific effect of cell stress induced by protein overexpression, we added the general lipoxygenase inhibitors 5,8,11,14-eicosatetraynoic acid (ETYA) and nordihydroguaiaretic acid (NDGA) after 15-LOX-1 transfection and found that the inhibition of 15-LOX-1 activity resulted in significantly reduced chemokine induction ( Fig. 2A) .
To further confirm that the chemokine induction effect of 15-LOX-1 was specific, the 15-LOX-1 expression vector pLPIRESneo/15-LOX-1 was cotransfected with siRNA targeting 15-LOX-1 (15-LOX-1 i) or nonspecific siRNA into A549 cells. The amount of 15-LOX-1 mRNA was reduced to approximately one-half by 15-LOX-1 siRNA compared with nonspecific siRNA at 24 h posttransfection (Fig. 2B) . Concomitantly, the 15(S)-HETE levels were reduced to the same extent (Fig. or unspecific control siRNA (Control i). Total RNA was isolated 24 h posttransfection, and mRNA levels were measured by real-time PCR (n ϭ 4). 15-LOX-1 activity was also measured as described in MATERIALS AND METHODS. Bar, SE. *P Ͻ 0.05. 2B). When 15-LOX-1 activity was knocked down by siRNA, the induction of MIP-1␣, RANTES, and IP-10 was also significantly attenuated (Fig. 2B) . Together, these data indicate that the chemokine induction effect of 15-LOX-1 upregulation in A549 cells is linked to 15-LOX-1 expression.
Furthermore, we measured the concentration of chemokines in conditioned medium of cells ectopically expressing 15-LOX-1. A time course study using ELISA showed that after 2 days of transfection, cells expressing 15-LOX-1 produced higher amounts of MIP-1␣ than cells transfected with control vector (Fig. 3A) . Multiplex luminex analysis demonstrated that conditioned medium of A549 cells expressing 15-LOX-1 had significantly higher levels of RANTES and IP-10 than that of cells transfected by empty vector (Fig. 3B) . The multiplex luminex analysis system also includes detection of eotaxin, GRO-1, MIG, MCP-2, and MCP-3, but they remained under the detection level. These results suggest that 15-LOX-1 overexpression induces chemokine production in A549 cells.
A549 Cells Overexpressing 15-LOX-1 Increase Migration of iDC
iDC express receptors for inflammatory chemokines, including CC chemokine receptor 1 (CCR1), CCR2, and CCR5, which guide them to inflammatory sites where antigen sampling can take place (25, 37) . Since 15-LOX-1 overexpression results in upregulation of MIP-1␣, MIP1-1␤, and RANTES, we performed chemotaxis assays to determine if the ectopic expression of 15-LOX-1 in A549 cells could induce the migration of iDC in vitro. We found that iDC exhibited significantly increased migration in response to the conditioned medium of A549 cells overexpressing 15-LOX-1 compared with medium of A549 cells transfected with the mock vector (Fig. 4A) . To establish if the increased iDC migration is dependent on 15-LOX-1-induced chemokine production, the conditioned medium was supplemented with antibodies against MIP-1␣, MIP-1␤, RANTES, or a mix of MIP-1␣ and RANTES antibodies in the chemotaxis assays. The antibody neutraliza- tion experiments demonstrated that the enhanced iDC migration was highly dependent on the MIP-1␣ and RANTES induced by 15-LOX-1 (Fig. 4A) . These experiments show that overexpression of 15-LOX-1 in A549 cells increases iDC migration by inducing expression of MIP-1␣ and RANTES.
15-LOX-1 Overexpression Upregulates Migration of Activated T Cells
T cells play a critical role in immune responses, and activated T cells have abundant expression of chemokine receptors, including CCR3 and CXCR3 (39) . We performed chemotaxis assays to study if the ectopic expression of 15-LOX-1 in A549 cells could induce the migration of PHA and IL-2 activated T cells. Activated T cells exhibited significantly enhanced migration toward the conditioned medium of A549 cells overexpressing 15-LOX-1 compared with medium of A549 cells transfected with mock vector (Fig. 4B) . To assess if the increased T cell migration is a direct effect of induced chemokine expression by ectopic expression of 15-LOX-1, antibodies against RANTES, IP-10, and I-TAC were added to the conditioned medium. The antibody neutralization experiments demonstrated that the enhanced activated T cell migration was mainly dependent on RANTES, although IP-10 and I-TAC also contributed to the increased T cell chemotaxis, but to a lesser extent (Fig. 4B ). This set of experiments demonstrates that 15-LOX-1 upregulation increases T cell migration predominantly by inducing increased release of RANTES.
A549 Cells Expressing 15-LOX-1 Increase Chemotaxis of Mast Cells
Mast cells are important players in the pathogenesis of asthma and other allergic diseases, and chemokines are involved in the accumulation of mast cells in inflamed tissues through a set of chemokine receptors including CXCR2, CCR3, and CCR5 (27) . Chemotaxis assays were performed to investigate if the ectopic expression of 15-LOX-1 in A549 cells could induce chemotaxis of mast cells. As shown in Fig. 4C , mast cells derived from cord blood exhibited significantly enhanced migration in response to the conditioned medium of A549 cells overexpressing 15-LOX-1 compared with medium of A549 cells transfected with empty vector. To confirm that the enhanced mast cell migration is a direct result of 15-LOX-1-induced chemokine release, antibodies raised against MIP1-␣ were added to the conditioned medium during the migration assay. These experiments show that 15-LOX-1-induced mast cell migration is highly dependent on MIP-1␣ (Fig. 4C) .
15-LOX-1 Ectopic Expression Upregulates NF-B Activity
To study the underlying mechanism(s) whereby 15-LOX-1 overexpression induces chemokine expression, A549 cells were incubated with 15(S)-HPETE, 15(S)-HETE, 13(S)-HPOTE, or 13(S)-HODE in 50 M for 24 h followed by quantitative RT-PCR. We did not observe upregulated expression of MIP1-␣ mRNA (Fig. 5A) , indicating that 15-LOX-1 increases chemokine expression by other mechanism(s). Several of the 15-LOX-1-induced chemokine genes contain NF-B binding sites in their corresponding promoter regions. NF-B is a transcription factor that responds to oxidative stress, which in turn can be the result of 15-LOX-1 expression (31) . We therefore performed experiments in which A549 cells were cotransfected with the 15-LOX-1 expression vector and a NF-B binding element-containing luciferase reporter plasmid. The obtained data showed that 15-LOX-1 expression can upregulate NF-B activity (Fig. 5B) , suggesting NF-B as a possible mediator of 15-LOX-1-induced chemokine gene transcription.
DISCUSSION
The role of 15-LOX-1 and its metabolites in the pathogenesis of airway inflammation is still elusive. 15-LOX-1 is constitutively expressed in the airway epithelium in healthy subjects, but several studies demonstrate increased amounts of 15-LOX-1 protein and 15-LOX-1 activity in the lungs of patients with asthma and chronic obstructive pulmonary disease (COPD) (7, 33) . IL-4 and -13 play an important role in the pathophysiology of asthma and may be responsible for the increased expression of 15-LOX-1 in the respiratory tract in this disease. Data obtained in certain clinical and experimental studies suggest inhibition of 15-LOX-1 as a possible therapeutic intervention in the setting of asthma, whereas interpretation of other studies indicates an anti-inflammatory role of the enzyme. However, several cell types in the respiratory tract possess the potential to express 15-LOX-1, including bronchial epithelial cells, alveolar macrophages, eosinophils, and mast cells (14, 20, 35, 36) , inferring a need to explore the consequences of its expression at the cell type-specific level.
In the past, the role of the airway epithelium cells in the pathogenesis of asthma has attracted more attention. Accumu- lating evidence suggests an aberrantly functioning epithelium in this disease, including deregulated antioxidant defense (10) and secretion of growth factors, chemokines, and eicosanoids, ultimately contributing to inflammation and airway wall remodeling (6) .
In the present study, the biological effects of 15-LOX-1 expression in cultured human lung epithelial cells were addressed. Transient 15-LOX-1 transfection of the A549 cell line was chosen as a model system due to this cell line's endogenous capacity to express the enzyme upon IL-4 stimulation, albeit at low protein and activity levels (data not shown). Following transfection and confirmation of 15-LOX-1 enzymatic activity, microarray analysis was applied as a first screening procedure. We found that ectopic expression of 15-LOX-1 in A549 cells leads to enhanced transcription of several chemokine genes. Among them, MIP-1␣, RANTES, and IP-10 were selected for further analysis because they are known to be highly involved in the chemotactic response of iDC, activated T cells, and mast cells. However, the mechanism(s) by which 15-LOX-1 induces chemokine gene expression is not clear. Oxidative stress has been reported to promote transcription of certain chemokine genes, and knocking down endogenous 12/15-LOX in a differentiated mouse monocytic cell line resulted in reduced oxidative stress (21) . Furthermore, 15-LOX-1 metabolites have been reported to bind and activate the nuclear receptor family peroxisome proliferator-activated receptor to induce transcription of downstream genes (2) . When the A549 cells were incubated with the 15-LOX-1-derived metabolites 15(S)-HPETE, 15(S)-HETE, 13(S)-HPOTE, or 13(S)-HODE for 24 h, we did not observe any induction of MIP-1␣ expression, indicating that the observed 15-LOX-1-dependent chemokine upregulation may not relate to these specific metabolites.
The microarray experiments also revealed other 15-LOX-1-induced nonchemokine genes that are involved in immunological reactions, including HLA-E, TAP1, TAP2, and tapasin of the MHC class I antigen processing machinery (AMP) gene family (data not shown). Most AMP genes share NF-B and IRF-3 binding sites in their promoter regions and could be activated by oxidative stress and in adaptive immune responses (29) .
Pathophysiologically, asthma is characterized by the accumulation of mast cells, T cells, and dendritic cells at the site of inflammation. Here, we show that conditioned medium from cultured lung epithelial A549 cells expressing 15-LOX-1 induces chemokine-specific chemotaxis of all these cell types.
Collectively, our data suggest that expression of 15-LOX-1 in airway epithelial cells, by induction of chemokine synthesis and release, contributes to the accumulation of inflammatory cells seen in airway inflammatory conditions. This observation indicates that 15-LOX-1 plays a proinflammatory role in the airway epithelium and might constitute a therapeutic target in asthma and other inflammatory lung disorders, such as COPD.
